Delray Beach, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The global IVD reagents market growth is primed to transition from USD 60.4 million in 2024 to USD 87.4 million by 2029, showcasing a strong CAGR of 7.7%. Growth in the IVD reagents market is primarily driven by innovations in molecular diagnostics aimed at improving diagnostic accuracy. Increasing awareness of preventive healthcare for early detection is also contributing to market growth. Additionally, the rising prevalence of chronic conditions is a significant factor driving the market's expansion. The growing adoption of next-generation sequencing (NGS) for genetic testing and the rising demand for advanced point-of-care testing are key factors propelling market growth. Furthermore, the growth of companion diagnostics is emerging as an important trend in the IVD reagents market. The increasing number of patients with chronic disorders such as cancer and cardiovascular diseases, along with a rise in research and development funding within the pharmaceutical industry, is expected to further boost the demand for IVD reagents.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131261429
Browse in-depth TOC on “IVD Reagents Market”
536 - Tables
59 - Figures
423 - Pages
The IVD reagents market is divided into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes and other IVD reagents based on type. In the year 2023, the IVD reagents market was dominated by the antibodies. The large share of the antibodies is attributed to its wide range of applications in diagnostics specifically in immunoassays.
The IVD reagents market is divided into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, immunohistochemistry based on technology. In the year 2023, the IVD reagents market was dominated by the immunoassays. The large share of the immunoassay technology is attributed to high levels of sensitivity and specificity.
The IVD reagents market is divided into infectious diseases, oncological applications, endocrinological applications, cardiological applications, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, and other applications segments based on application. In 2023, the IVD reagents market was dominated by the infectious diseases. The large share of the male patient’s segment is attributed to the growing adoption of point-of-care testing, and high global burden of diseases such as respiratory infections.
The global IVD reagents market has been segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. North America accounted for the largest share of the IVD reagents market in 2023, which is followed by, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The large share of North America can be attributed the increasing healthcare expenditure in the region, and the presence of some of the leading clinical laboratories.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=131261429
The IVD reagents market is fragmented, with top companies holding significant market shares. The top three players in this market include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany). Players in this market are focusing on adopting organic and inorganic growth strategies such as expansions, and acquisitions to increase their IVD reagents portfolio, cater to customer needs, increase their profitability and expand their presence in the global IVD reagents market.
F. Hoffmann-La Roche Ltd (Switzerland):
F. Hoffmann-La Roche Ltd is leading with the highest market share in the IVD reagents market. It has a strong portfolio of IVD reagents products. F. Hoffmann-La Roche Ltd offers a strong product portfolio featuring FDA- and CE-marked approved reagents, which played a key role in sustaining its competitive market presence. The Diagnostics Division observed a 7% jump in base business sales revenue which is majorly due to growth in immunodiagnostic products focused on cardiac testing and diagnostic solutions.
Abbott (US):
Abbott is the second largest player in our market. The company has a very strong innovation and product development portfolio. It has 21 manufacturing site dedicated towards diagnostic products. The company derives significant revenues from North America, specifically the US. To further expand the market presence and maintain its position in the market, Abbott focuses on organic & inorganic strategies, such as product launches, acquisitions, and collaborations. For instance, in 2023 Abbott (US) has collaborated with The America Diabetes Association (US) for technology innovation focused on diabetes diagnosis.
Danaher Corporation (US):
Danaher Corporation is the third largest player in the IVD reagents market. The company has wide geographical presence across the Americas, Europe, the Middle East & Africa, and the Asia Pacific. Danaher Corporation also aims to expand its sales force in North America region and focuses on international expansions. In March 2023, Danaher Corporation launched its first 77,000 sq. ft manufacturing facility in India.
For more information, Inquire Now!
Related Reports:
Medical Device Engineering Market
Medical Device Contract Manufacturing Market
IVD Contract Manufacturing Market
Get access to the latest updates on IVD Reagents Companies and IVD Reagents Market Size
